The Global Market for High Throughput Screening is Projected to Exceed US$22.5 Billion by 2022

Soaring Investments in the Healthcare Sector and the Shift Towards High Throughput Research Drive Growth in the Global High Throughput Screening Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global High Throughput Screening market. The global market for High Throughput Screening is projected to exceed US$22.5 billion by 2022, driven by increasing R&D spending, shift towards high throughput research, expansion of use in biochemical applications, unparalleled  advantages in compound screening, and overall positive prognosis across end-use markets.

High throughput screening (HTS) is a scientific experimentation technique principally used in drug discovery programs. HTS made rapid progress over the past two decades to emerge as an innovative multi-disciplinary branch within the broader biochemistry sector combining aspects such as biology, medicinal chemistry, and laboratory automation. Prominent factor benefiting market expansion is HTS’ ability to extend a reliable platform to screen large number of compounds against vast number of targets in a specified time, to generate more hits, and subsequently more lead compounds, and eventually more new drugs. Modern HTS systems integrate technologies such as liquid handling devices, robotics, sensitive detectors, and data processing & control software, to help implement hundreds and thousands of pharmacological, chemical, and/or genetic tests on the screening specimen in a very short span of time. Since HTS relies on automation and detectors/sensors, faster identification of active compounds, antibodies or genes, bearing influence on bimolecular pathways, can be done effortlessly.

HTS is now being utilized in various technology formats including cell-based assay, label-free, lab-on-a-chip, and bioinformatics, each of which require specialized techniques for arriving at results with HTS mechanism. Cell-based HTS, which is expected to drive future market growth, has already established its proficiency in early-stage drug discovery programs, and about 55-60% of assays for target validation in drug discovery are based on cell-based HTS model. With technological approaches in modern laboratories becoming reliable, robust and sensitive, adoption of cell-based HTS developed into a natural choice in drug discovery applications. For HTS processes, LOC technology offers significant benefits such as low fluid consumption, quicker analysis, faster turnaround times, and low wastage and higher process efficiency. In line with growing adoption of HTS technologies, demand for various HTS instruments, consumables/reagents, software, and services is exhibiting faster growth. A modern HTS facility integrates various elements including HTS instruments such as microplate handling systems and liquid handling devices; consumables and reagents such as cell lines, dyes, and labelling solutions; and software for analysis and interpretation of screening data. Expediting the screening process, HTS technologies find favor among life sciences enterprises including pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic and government R&D facilities.

As stated by the new market research report on High Throughput Screening, the United States represents the largest market worldwide, followed by Europe and supported by effervescent drug discovery activity. Asia-Pacific ranks as the fastest growing market with a CAGR of 9.2% over the analysis period led by increased investments in life sciences research and healthcare infrastructure especially clinical diagnostics in countries such as China, India, South Korea, Taiwan and Indonesia; and fast paced enhancements in the combinatorial chemistry, and genomics especially in the Chinese drug discovery outsourcing market.

Key players covered in the report include Agilent Technologies, Inc., Aurora Biomed, Inc., Axxam SpA, BD Biosciences, Danaher Corp., Beckman Coulter, Inc., Molecular Devices, Inc., Bio-Rad Laboratories, Inc., BioTek Instruments Inc., BMG LABTECH GmbH, Charles River Laboratories International, Inc., Corning Inc., DiscoveRx Corp., Evotec AG, F. Hoffmann-La Roche Ltd., ForteBio, Genedata AG, IntelliCyt® Corp., Luminex Corp., PerkinElmer, Inc., Sigma-Aldrich Corp., Tecan Group Ltd., and Thermo Fisher Scientific Inc., among others.

The research report titled “High Throughput Screening: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, issues, mergers, acquisitions, and other strategic industry activities of major players worldwide. The report provides market estimates and projections for all major geographic markets including the United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China, India and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America), and Rest of World. Product types analyzed for the global market include Consumables/Reagents, Instruments, and Software & Services. The report also analyses the global market by technology types - Label-Free Technology, Cell-Based Assay, and Others.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.